Reveal SNP Microarray - Oncology

This test will detect chromosomal imbalance that may be present in neoplastic disorders and clonal evolution. It provides detection of copy-neutral loss of heterozygosity of any chromosome, and the percent and location of homozygosity, that may be associated with cancer gene mutations.

Pertinent medical findings should accompany the test request form.

This SNP assay does not detect balanced rearrangements, low-level mosaicism (<10%), marker chromosomes that only that only contain heterochromatin or tetraploidy.

This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.

SNP microarray analysis is performed using the Cytoscan® HD Accel platform, which uses more than 743,130 SNP probes and 2,029,441 NPCN probes with a median spacing of 0.818 kb.